Transparency of high‐dimensional propensity score analyses: Guidance for diagnostics and reporting

MLA

John Tazare, et al. “Transparency of High‐dimensional Propensity Score Analyses: Guidance for Diagnostics and Reporting.” Pharmacoepidemiology and Drug Safety, vol. 31, Feb. 2022, pp. 411–23. EBSCOhost, https://doi.org/10.1002/pds.5412.

APA

John Tazare, Richard Wyss, Jessica M. Franklin, Liam Smeeth, Stephen J. W. Evans, Shirley V. Wang, Sebastian Schneeweiss, Ian J. Douglas, Joshua J. Gagne, & Elizabeth J. Williamson. (2022). Transparency of high‐dimensional propensity score analyses: Guidance for diagnostics and reporting. Pharmacoepidemiology and Drug Safety, 31, 411–423. https://doi.org/10.1002/pds.5412

Chicago

John Tazare, Richard Wyss, Jessica M. Franklin, Liam Smeeth, Stephen J. W. Evans, Shirley V. Wang, Sebastian Schneeweiss, Ian J. Douglas, Joshua J. Gagne, and Elizabeth J. Williamson. 2022. “Transparency of High‐dimensional Propensity Score Analyses: Guidance for Diagnostics and Reporting.” Pharmacoepidemiology and Drug Safety 31 (February): 411–23. doi:10.1002/pds.5412.